circ_KIAA1429 accelerates hepatocellular carcinoma advancement through the mechanism of m6A-YTHDF3-Zeb1

Wang, Maoyu; Yang, Yongliang; Yang, Jing; Yang, Juanjuan; Han, Sileny

doi:10.1016/j.lfs.2020.118082

Cited by 95 publications

(86 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…132,133 Besides, VIRMA was also defined as an oncogene in HCC. 134,135 Pancreas Cancer. Pancreas cancer is recognized as a kind of high-grade malignant neoplasm.…”

Section: Review Llmentioning

confidence: 99%

RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications

Shi

Dai

et al. 2020

The Innovation

View full text Add to dashboard Cite

N 6 -Methyladenosine (m 6 A) RNA modification brings a new dawn for RNA modification researches in recent years. This posttranscriptional RNA modification is dynamic and reversible, and is regulated by methylases (“writers”), demethylases (“erasers”), and proteins that preferentially recognize m 6 A modifications (“readers”). The change of RNA m 6 A modification regulates RNA metabolism in eucaryon, including translation, splicing, exporting, decay, and processing. Thereby the dysregulation of m 6 A may lead to tumorigenesis and progression. Given the tumorigenic role of abnormal m 6 A expression, m 6 A regulators may function as potential clinical therapeutic targets for cancers. In this review, we emphasize on the underlying mechanisms of m 6 A modifications in tumorigenesis and further introduce the potential m 6 A regulators-associated therapeutic targets for tumor therapy.

show abstract

“…132,133 Besides, VIRMA was also defined as an oncogene in HCC. 134,135 Pancreas Cancer. Pancreas cancer is recognized as a kind of high-grade malignant neoplasm.…”

Section: Review Llmentioning

confidence: 99%

RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications

Shi

Dai

et al. 2020

The Innovation

View full text Add to dashboard Cite

show abstract

“…In the correlation analysis, KIAA1429 was found to present the strongest correlation with YTHDF3. A previous study found that YTHDF3 could enhance the mRNA stability of Zeb1, the downstream target of KIAA1429, thus leading to cell metastasis in HCC [42]. This may contribute to the strong correlation between the two genes.…”

Section: Discussionmentioning

confidence: 91%

Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of esophageal adenocarcinoma

Zhou¹,

Li²,

Zou³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundN6-methyladenosine (m6A) is an abundant modification in RNAs that affects RNA metabolism, and it is reported to be closely related to cancer occurrence and metastasis. The aim of this study was to identify novel prognostic biomarkers by using m6A RNA methylation regulators capable of improving the risk-stratification criteria of survival for esophageal adenocarcinoma patients.MethodsThe gene expression data of 16 m6A methylation regulators and its relevant clinical information were extracted from The Cancer Genome Atlas (TCGA) database. The expression pattern of these m6A methylation regulators was evaluated. Consensus clustering analysis was conducted to identify clusters of esophageal adenocarcinoma patients with different prognosis. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were performed to construct multiple-gene risk signature. A survival analysis was carried out to determine the prognosis significance.ResultsTen m6A methylation regulators (HNRNPA2B1, HNRNPC, YTHDF1, METTL3, YTHDF2, RBM15, YTHDC1, WTAP, KIAA1429 and YTHDF3) showed significant up-regulation in tumor tissue. Consensus clustering analysis identified three clusters of esophageal adenocarcinoma patients with different overall survival. A five-gene signature, HNRNPA2B1, KIAA1429, WTAP, METTL16 and ALKBH5, was constructed to serve as a prognostic indicator for distinguish esophageal adenocarcinoma patients with different prognosis. The receiver operator characteristic (ROC) curve which indicated the area under the curve (AUC) were 0.803, demonstrated that the prognostic signature had preferable prediction efficiency.Conclusionsm6A methylation regulators exert as potential biomarkers for prognostic stratification of esophageal adenocarcinoma patients and might help clinicians make individualized therapy for this patient population.

show abstract

“…Interestingly, the inhibition of YTHDF2 selectively targeted leukemic stem cells (LSCs) in AML, indicating the potential functions of circRNA regulated YTHDF2 in the progression of AML [88]. In addition, circ_KIAA1429 could promote the progression of HCC by regulating the m 6 A-YTHDF3-Zeb1 [89]. It was confirmed that SNHG14/miR-5590-3p/Zeb1 axis enhanced the progression and immune evasion through regulating PD-1/PD-L1 checkpoint in DLBCL, which provide an innovative perspective for circRNA mediated immunotherapy of lymphoma [90].…”

Section: Function Of Circrnas In Ferroptosismentioning

confidence: 99%

The functions and clinical significance of circRNAs in hematological malignancies

et al. 2020

View full text Add to dashboard Cite

With covalently closed circular structures, circular RNAs (circRNAs) were once misinterpreted as by-products of mRNA splicing. Being abundant, stable, highly conserved, and tissue-specific, circRNAs are recently identified as a type of regulatory RNAs. CircRNAs bind to certain miRNAs or proteins to participate in gene transcription and translation. Emerging evidence has indicated that the dysregulation of circRNAs is closely linked to the tumorigenesis and treatment response of hematological malignancies. CircRNAs play critical roles in various biological processes, including tumorigenesis, drug resistance, tumor metabolism, autophagy, pyroptosis, and ferroptosis. The N6-methyladenosine modification of circRNAs and discovery of fusion-circRNAs provide novel insights into the functions of circRNAs. Targeting circRNAs in hematological malignancies will be an attractive treatment strategy. In this review, we systematically summarize recent advances toward the novel functions and molecular mechanisms of circRNAs in hematological malignancies, and highlight the potential clinical applications of circRNAs as novel biomarkers and therapeutic targets for future exploration.

show abstract

circ_KIAA1429 accelerates hepatocellular carcinoma advancement through the mechanism of m6A-YTHDF3-Zeb1

Cited by 95 publications

References 39 publications

RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications

RNA m6A Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications

Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of esophageal adenocarcinoma

The functions and clinical significance of circRNAs in hematological malignancies

Contact Info

Product

Resources

About